According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is โฌ55.66 Million. In 2024 the company made a revenue of โฌ0.17 Billion an increase over the revenue in the year 2023 that were of โฌ54.53 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.